News/ News/ R&D Novo’s oral semaglutide on target in phase 3 trial Richard Staines Diabetes, Eli Lilly, Novo Nordisk, Oramed, semaglutide 0 Comment Novo Nordisk continues to build a case for its oral semaglutide GLP-1 class diabetes drug, with latest results Share X Novo’s oral semaglutide on target in phase 3 trial https://pharmaphorum.com/news/novos-oral-semaglutide-target-phase-3-trial/
Diabetes, Eli Lilly, Novo Nordisk, Oramed, semaglutide
0 Comment
